The effect of nicotinic acid and alcohol co-administration in Wistar rats

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 27, Issue 1, 2005, Pages 17-23

  Kolovou, Genovefa D ^a   Mikhailidis, D P ^b   Adamopoulou, E N ^a   Salpea, K D ^a   Kafaltis, N ^a   Bilianou, H G ^c   Malakos, J ^a   Pilatis, N D ^a   Mykoniatis, M ^d   Cokkinos, D V ^a  

^a ONASSIS CARDIAC SURGERY CENTER   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c TZANEIO GENERAL HOSPITAL OF PIRAEUS   (Greece)

^d UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Alcohol; Hepatic enzymes; Nicotinic acid; Triglycerides

Indexed keywords

ALANINE AMINOTRANSFERASE; ALCOHOL; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FATTY ACID; G PROTEIN COUPLED RECEPTOR; LIVER ENZYME; NICOTINIC ACID; OLIVE OIL; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ALCOHOL INTERACTION; DRUG EFFICACY; DYSLIPIDEMIA; FATTY LIVER; HISTOPATHOLOGY; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; LIVER FUNCTION; LIVER TOXICITY; MALE; NONHUMAN; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; DRUG INTERACTIONS; ETHANOL; LIVER; LIVER FUNCTION TESTS; MALE; NIACIN; RATS; RATS, WISTAR; TRIGLYCERIDES;

EID: 20144383819     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2005.27.1.875432     Document Type: Article

References (66)

1. Walldius, G., Wahlberg, G. Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. In: Drugs Affecting Lipid Metabolism VIII. Kritchevsky, D., Holmes, W.L., Paoletti, R. (Eds.). Plenum: New York 1985, 281-281.
2. Carlson, L.A. Effects of nicotinic acid on serum lipids and lipoproteins. In: Treatment of Hyperlipoproteinemia. Carlson, L.A., Osslon, A.G. (Eds.). Raven Press: New York 1984, 115.
3. Blum, C.B., Levy, R.I. Current therapy of hypercholesterolemia. JAMA 1989, 261: 3582-7.
4. Canner, P.L., Berge, K.G., Wenger, N.K. et al. Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. J Am Coll Cardiol 1986, 8: 1245-55.
5. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease (the Coronary Drug Project). JAMA 1975, 231: 360-81.
6. Tatò, F., Vega, G.L., Grundy, S.M. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998, 81: 805-8.
7. Wise, A., Foord, S.M., Fraser, N.J. et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003, 278: 9869-74.
8. Tunaru, S., Kero, J., Schaub, A. et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003, 9: 352-5.
9. Karpe, F., Frayn, K.N. The nicotinic acid receptor-A new mechanism for an old drug. Lancet 2004, 363: 1892-4.
10. Rubic, T., Trottmann, M., Lorenz, R.L. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004, 67: 411-19.
11. Dukes, M.N.G. Nicotinic acid and its derivatives. In: Meyler's Side Effects of Drugs. Elsevier: Amsterdam 1998, 923.
12. Miettinen, T.A., Taskinen, M.R., Pelkonen, R., Nikkilä, E.A. Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid. Acta Med Scand 1969, 186: 247-53.
13. Basu, T.K., Makhani, N., Sedgwick, G. Niacin (nicotinic acid) in non-physiological closes causes hyperhomocysteineaemia in Sprague-Dawley rats. Br J Nutr 2002, 87: 115-9.
14. Patterson, D.J., Dew, E.W., Gyorkey, F., Graham, D.Y. Niacin hepatitis. South Med J 1983, 76: 239-41.
15. Grundy, S.M., Mok, H.Y., Zech, L., Berman, M. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981, 22: 24-36.
16. Tolman, K.G. Defining patient risks from expanded preventive therapies. Am J Cardiol 2000, 85: 15E-9E.
17. Clementz, G.L., Holmes, A.W. Nicotinic acid-induced fulminant hepatic failure. J Clin Gastroenterol 1987, 9: 582-4.
18. Bays, H.E. Extended-release niacin/lovastatin: The first combination product for dyslipidemia. Expert Rev Cardiovasc Ther 2004, 2: 485-501.
19. Ruitenberg, A., van Swieten, J.C., Witteman, J.C. et al. Alcohol consumption and risk of dementia: The Rotterdam Study. Lancet 2002, 359: 281-6.
20. Papadakis, J.A., Ganotakis, E.S., Mikhailidis, D.P. Beneficial effect of moderate alcohol consumption on vascular disease: Myth or reality? J R Soc Health 2000, 120: 11-5.
21. Mikhailidis, D.P., Jeremy, J.Y., Barradas, M.A., Green, N., Dandona, P. The effect of ethanol on vascular prostacyclin synthesis, platelet aggregation and platelet thromboxane release. Br Med J 1983, 287: 1495-8.
22. Brodie, B.B., Butler, W.M., Horning, M.C., Maickel, R.P., Maling, H.M. Alcohol induced triglyceride deposition in liver through derangement of fat transport. Am J Clin Nutr 1961, 9: 432.
23. Reboucas, G., Isselbacher, K.J. Studies on the pathogenesis of the ethanol-induced fatty liver. l. Synthesis and oxidation of fatty acids by the liver. J Clin Invest 1961, 40: 1355.
24. Goldberg, I.J., Mosca, L., Piano, M.R., Fisher, E.A., Nutrition Committee, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing of the American Heart Association. AHA Science Advisory: Wine and your heart: A science advisory for healthcare professionals from the Nutrition Committee, Council on Epidemiology and Prevention, and Council on Cardiovascular Nursing of the American Heart Association. Circulation 2001, 103: 472-5.
25. Kolovou, G.D., Mikhailidis, D.P., Daskalova, D.C. et al. The effect of co-administration of simvastatin and alcohol in rats. In Vivo 2003, 17: 523-8.
26. Kolovou, G.D., Mikhailidis, D.P., Kafaltis, N. et al. The effect of alcohol and gemfibrozil co-administration in Wistar rats. In Vivo 2004, 18:49-54.
27. The American Association for Accreditation of Laboratory Animal Care. JAMA 1969, 207: 1707.
28. Margeli, A., Theocharis, S., Skaltsas, S. et al. Effect of cadmium pre-treatment on liver regeneration after partial hepatectomy in rats. Arch Toxicol 1994, 68: 85-90.
29. Margeli, A.P., Skaltsas, S.D., Spiliopoulou, C.A., Mykoniatis, M.G., Theocharis, S.E. Hepatic stimulator substance activity in the liver of thioacetamide-intoxicated rats. Liver 1999, 19: 519-25.
30. Theocharis, S.E., Margeli, A.P., Agapitos, E.V., Mykoniatis, M.G., Kittas, C.N., Davaris, P.S. Effect of hepatic stimulator substance administration on tissue regeneration due to thioacetamide-induced liver injury in rats. Scand J Gastroenterol 1998, 33: 656-63.
31. Sorrell, M.F., Baker, H., Tuma, D.J., Frank, O., Barak, A.J. Potentiation of ethanol fatty liver in rats by chronic administration of nicotinic acid. Biochim Biophys Acta 1976, 450: 231-8.
32. Lieber, C.S., Spritz, N., DeCarli, L.M. Role of dietary, adipose, and endogenously synthesized fatty acids in the pathogenesis of the alcoholic fatty liver. J Clin Invest 1966. 45: 51-62.
33. Altschul, R., Hoffer, A., Stephen, J.D. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955, 54: 558-9.
34. Carlson, L.A., Oro, L. The effect of nicotinic acid on the plasma free fatty acid; demonstration of a metabolic type of sympathicolysis. Acta Med Scand 1962, 172: 641-5.
35. Canner, P.L., Berge, K.G., Wenger, N.K. et al. Fifteen year mortality in coronary drug project patients: Long-term benefit with niacin. J Am Coll Cardiol 1986, 8: 1245-55.
36. Carlson, L.A., Rosenhamer, G. Reduction of mortality in the Stockholm Ischaemic heart disease secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand 1988, 223: 405-18.
37. DiPalma, J.R., Thayer, W.S. Use of niacin as a drug. Annu Rev Nutr 1991, 11: 169-87.
38. Weiner, M., Redisch, W., Steele, J.M. Occurrence of fibrinolytic activity following administration of incotinic acid. Proc Soc Exp Biol Med 1958, 98: 755-7.
39. Carlson, L.A., Oro, L. Effect of treatment with nicotinic acid for one month on serum lipids in patients with different types of hyperlipidemia. Atherosclerosis 1973, 18: 1-9.
40. Kane, J.P., Tun, P., Malloy, M.J., Havel, R.J. Heterozygous familial hypercholesterolemia: Treatment with combined drug regimens. Clin Res 1978, 26: 529.
41. Langer, T., Levy, R.I. The effect of nicotinic acid on turnover of low density lipoproteins in Type II hyperlipoproteinemia. In: Metabolic Effects of Nicotinic Acid and its Derivatives. Gey, K.F., Carlson, L.A. (Eds.). Huber, Bern: New York 1971, 641.
42. Eisenberg, D., Bilheimer, D.W., Levy, R.I. Lingren, F.I. On the metabolic conversion of human plasma very low density lipoprotein to low density lipoprotein. Biochim Biophys Acta 1973, 326: 361-7.
43. Perret, B., Ruidavets, J.B., Vieu, C. et al. Alcohol consumption is associated with enrichment of high-density lipoprotein particles in polyunsaturated lipids and increased cholesterol esterification rate. Alcohol Clin Exp Res 2002, 26: 1134-40.
44. Bays, H.E., Dujovne, C.A., McGovern, M.E. et al. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003, 91: 667-72.
45. McKenney, J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004, 164: 697-705.
46. Frank, O., Baker, H., Sobotka, H. Blood-and serum-levels of water-soluble vitamins in man and animals. Nature 1963, 197: 4901.
47. Carlson, L.A., Hanngren, A. Initial distribution in mice of 3H-labeled nicotinic acid studied with autoradiography. Life Sci 1964, 3: 867-71.
48. Rubin, E., Lieber, C.S. Alcohol-induced hepatic injury in nonalcoholic volunteers. N Engl J Med 1968, 278: 869-76.
49. Conney, A.H. Pharmacological implications of microsomal enzyme induction. Pharmacol Rev 1967, 19: 317-66.
50. Kraemer, K.L., Mayo-Smith, M.F., Calkins, D.R. Independent clinical correlates of severe alcohol withdrawal. Subst Abus 2003, 24: 197-209.
51. Nishimura, M., Hasumura, Y., Takeuchi. J. Effect of an intravenous infusion of ethanol on serum enzymes and lipids in patients with alcoholic liver disease. Gastroenterology 1980, 78: 691-5.
52. McKenney, J.M., Proctor, J.D., Harris, S., Chinchili, V.M. A comparison of the efficacy and toxic effects of sustained-vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994, 271: 672-7.
53. Dalton, T.A., Berry, R.S. Hepatotoxicity associated with sustained-release niacin. Am J Med 1992, 93: 102-4.
54. Capuzzi, D.M., Guyton, J.R., Morgan, J.M. et al. Efficacy and safety of an extended-release niacin (niaspan): A long term-study. Am J Cardiol 1998, 82: 74U-81U.
55. Gray, D.R., Morgan, T., Chretien, S.D., Kashyap, M.L. Efficacy and safety of controlled-release niacin in dyslipoproteinemic veterans. Ann Intern Med 1994, 121: 252-8.
56. Lieber, C.S., Spritz, N. Effects of prolonged ethanol intake in man: Role of dietary adipose, and endogenously synthesized fatty acids in the pathogenesis of the alcoholic fatty liver. J Clin Invest 1966, 45: 1400-11.
57. Gerson, R.J., Mac Donald, J.S., Alberts, A.W. et al. Animal safety and toxicology of simvastatin and related hydroxyl-methylglutaryl-coenzyme A reductase inhibitors. Am J Med 1989, 87: 28S-38S.
58. Bosma, A., Seifert, W.F., van Thiel-de Ruiter, G.C. et al. Alcohol in combination with malnutrition causes increased liver fibrosis in rats. J Hepatol 1994, 21: 394-402.
59. Rivin, A. U. Jaundice occurring during nicotinic acid therapy for hypercholesteremia. JAMA 1959, 170: 2088-9.
60. Winter, S.L., Boyer, J.L. Hepatic toxicity from large doses of vitamin B3 (nicotinamide). N Engl J Med 1973, 89: 1180-2.
61. Baggenstoss, A.H., Christensen, N.A., Berge, K.G., Baldus, W.P., Spiekerman, R.E. Fine structural changes in the liver in patients receiving nicotinic acid hypercholesteremia. Gastroenterol 1967, 52: 314.
62. Kohn, R.M., Montes, M. Hepatic fibrosis following long acting nicotinic acid therapy: A case report. Am J Med Sci 1969, 58: 94-9.
63. Knopp, R.H., Ginsberg, J., Albers, J.J. et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985, 4: 642-50.
64. Henkin, Y., Johnson, K.C., Segrest, J.P. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin. JAMA 1990, 64: 241-3.
65. Ginsberg, H., Olefsky, J., Farquhar, J.W., Reaven, G.M. Moderate ethanol ingestion and plasma triglyceride levels: A study in normal and hypertriglyceridemic persons. Ann Intern Med 1974, 80: 143-9.
66. Zhao, X.Q., Morse, J.S., Dowdy, A.A. et al. Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis treatment study). Am J Cardiol 2004, 93: 307-12.